Abstract
Mesenchymal stem cells (MSCs) play a crucial role in regenerative medicine due to their multifaceted potential and immunomodulatory effects. This study investigates molecular heterogeneity between bone marrow-derived (BM-MSC) and umbilical cord blood-derived (UCB-MSC) sources using an integrative bioinformatics approach on the GSE6029 dataset. The analysis identified 739 differentially expressed genes (DEGs); 374 of these were upregulated in UCB-MSCs and 365 in BM-MSCs. UCB-MSCs exhibited a rich transcriptomic profile in terms of RNA processing, proteasome, and spliceosome pathways, controlled by key genes such as MYC and HSPA4. In contrast, BM-MSCs showed significant enrichment in PI3K-Akt signaling, ECM-receptor interactions, and constitutive development. At the heart of this enrichment were the COL4A1 and MET genes. Post-transcriptional mapping identified miR-20b-5p as a key regulator in UCB-MSCs, while miR-15a-5p and miR-26a-5p were dominant in the BM-MSC regulatory network. These findings demonstrate that UCB-MSCs are molecularly specialized for rapid proliferation and immunomodulation, while BM-MSCs are optimized for structural integration and orthopedic repair. This study provides a strategic framework for resource selection and emphasizes that MSC selection should be tailored to the specific pathological requirements of clinical practice.